Loading...
•
Mar 31, 2024
Praxis Q1 2024 Earnings Report
Praxis Precision Medicines reported financial results for the first quarter 2024.
Key Takeaways
Praxis Precision Medicines reported a net loss of $39.6 million for the first quarter of 2024. The company's cash and investments reached $451.2 million as of April 30, 2024, extending the operational runway into 2027.
Made significant progress on all fronts in the first quarter.
Strengthened financial resources and reported positive photo paroxysmal response (PPR) results in PRAX-628.
Continued strong recruitment for the pivotal Essential3 trials in Essential Tremor (ET), with topline results expected in the second half of 2024.
Randomization in PRAX-562 Phase 2 EMBOLD study completed in pediatric patients with developmental and epileptic encephalopathies (DEEs), with topline results expected in the third quarter of 2024.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...